Home Cart Sign in  
Chemical Structure| 188817-13-2 Chemical Structure| 188817-13-2

Structure of SC-560
CAS No.: 188817-13-2

Chemical Structure| 188817-13-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SC-560 is a highly selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.009 and 6.3 μM for COX-1 and COX-2 respectively). It inhibits COX-1-derived platelet thromboxane B2, gastric PGE2 and dermal PDE2 production and significantly reduces ovarian surface epithelial tumor growth in vivo.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SC-560

CAS No. :188817-13-2
Formula : C17H12ClF3N2O
M.W : 352.74
SMILES Code : FC(C1=NN(C2=CC=C(OC)C=C2)C(C3=CC=C(Cl)C=C3)=C1)(F)F
MDL No. :MFCD02179214
InChI Key :PQUGCKBLVKJMNT-UHFFFAOYSA-N
Pubchem ID :4306515

Safety of SC-560

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
IEC-6 cells 1 μM 72 hours SC-560 had no effect on Kv1.3 protein expression PMC4656099
Rat colonic tissue 300 nM 10 minutes To investigate the effect of COX-1 inhibitor SC-560 on colonic secretory responses, results showed SC-560 had no effect on Isc responses to EFS or IBMX PMC1773896
Human colonic longitudinal muscle cells 0.1 μM 30 minutes SC-560 enhanced electrically induced contractions, indicating the role of COX-1 in modulating cholinergic neurotransmission PMC1774510
Human colonic longitudinal smooth muscle preparations 0.1 μM 30 minutes In control tissues, SC-560 enhanced electrically evoked cholinergic contractions, but no effect was observed in tissues from DD patients. PMC4128069
T2 OSE cells 2, 5, or 10 μM 4 or 16 hours SC-560 dramatically inhibited PGI2 production in a dose-dependent manner. PMC2584020

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice T2 OSE cell allograft model Oral gavage 3 mg/kg Twice daily for 18 or 50 days SC-560 significantly inhibited tumor growth, whereas celecoxib had little effect. PMC2584020
Mice Partial hepatectomy model Oral gavage 10 mg/kg Twice daily until animal killing To investigate the effect of SC-560 on liver regeneration. The results show that inhibition of COX-1 (SC-560) tends to slightly delay liver regeneration, whereas inhibition of COX-2 (SC-236) significantly inhibits regeneration. Simultaneous inhibition of COX-1 and COX-2 (SC-560 + SC-236) results in marked inhibition of hepatic regeneration, similar to that seen with indocin (a non-selective COX inhibitor). PMC37530
Wistar rats Ethanol-induced gastric mucosal lesions model Intragastric administration 5 mg/kg Single dose SC-560 completely reversed the protective effect of curcumin against ethanol-induced gastric mucosal lesions PMC5910495
Wistar rats Normal gastric mucosa and acid-challenged gastric mucosa models Oral 5 and 20 mg/kg Single dose, assessed after 5 hours To assess the effect of SC-560 on normal and acid-challenged gastric mucosa, results showed no injury in normal stomach alone but dose-dependent injury in acid-challenged stomach PMC1572692
Rats Carbon tetrachloride-induced cirrhosis and ascites rat model Intravenous injection 20 mg/kg Single dose To evaluate the effects of SC-560 on renal function in cirrhotic rats with ascites. Results showed that SC-560 significantly decreased urinary sodium excretion, glomerular filtration rate, and renal plasma flow, and markedly impaired the diuretic and natriuretic responses to furosemide. PMC1573194
Sprague-Dawley rats Angiotensin II-induced hypertension model Oral gavage 5 mg/kg Once daily for two weeks To evaluate the effect of SC-560 on Ang II-induced vascular collagen deposition, results showed that SC-560 prevented Ang II-induced collagen deposition PMC3682704
Swiss Webster mice GAS myonecrosis model Intraperitoneal injection 6 mg/kg Every 12 hours for 72 hours The COX-1 selective NSAID (SC-560) alone did not significantly alter the disease course, but showed a trend toward improved survival (60% vs 20%) when combined with clindamycin. PMC3982845
Nude mice Human ovarian cancer SKOV-3 xenograft model Oral gavage 3 mg/kg Twice daily for 21 days To evaluate the effect of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts. Results showed that SC-560 combined with cisplatin or taxol significantly inhibited tumor growth, microvessel density (MVD), and vascular endothelial growth factor (VEGF) expression, with greater efficacy than cisplatin or taxol alone. PMC4227273

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.83mL

0.57mL

0.28mL

14.17mL

2.83mL

1.42mL

28.35mL

5.67mL

2.83mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories